Optimizing epilepsy management in teenagers

Adolescent-Onset Epilepsy: Clinical Features and Predictive Factors for First-Year Seizure Freedom

BACKGROUND

Teenagers with epilepsy require special attention to ensure a successful treatment journey. Our objective was to delineate the clinical characteristics of adolescent-onset epilepsy (AOE) and investigate the predictive factors influencing first-year seizure freedom.

METHODS

We retrospectively analyzed the medical records of patients whose first seizure occurred between the ages of 10 and 19 years and who received antiseizure medication (ASM) treatment for at least 12 months.

RESULTS

A total of 67 patients were included, with an average age of 13.5 ± 2.3 years at the onset of their first seizure. The average follow-up period was 45.2 ± 16.9 months, and comorbid conditions were present in 23 patients (34.3%). The majority of the patient population (83.6%) was affected by generalized epilepsy. The most common epilepsy syndrome was epilepsy with generalized tonic-clonic seizures alone at 70.1% (juvenile myoclonic epilepsy 11.9%, juvenile absence epilepsy 1.5%). Regarding ASM treatment, 31 patients (46.3%) received monotherapy, and 28 (41.8%) received dual therapy. Five patients (7.5%) encountered issues related to medication adherence. First-year seizure freedom was observed in 42 patients (62.7%). In multivariate analysis, a negative family history of epilepsy (odds ratio 12.1, 95% confidence interval 1.27-115.44, p = 0.030) was identified as a strong predictive factor of first-year seizure freedom, along with ASM monotherapy (odds ratio 3.99, 95% confidence interval 1.05-15.21, p = 0.043).

CONCLUSION

These findings suggest that AOE typically exhibits effective control of seizures. A negative family history of epilepsy and ASM monotherapy emerges as robust predictor of achieving favorable outcomes within the early stage of treatment.

Role of Perampanel in the Management of Pediatric Epilepsies in Asia: Expert Opinion

Management of pediatric epilepsies poses unique challenges around diagnosis, treatment options, comorbidities, and the potential for these factors to interact with processes in the developing brain. In pediatric patients, broad-spectrum antiseizure medications (ASMs) with minimal potential for adverse events (AEs) and limited impact on cognition and behavior are preferred. Perampanel is a first-in-class ASM with broad-spectrum efficacy, a tolerable safety profile, minimal negative impact on cognitive function, and other features that make it a viable treatment option in this patient population. However, evidence and experience of its use in pediatric patients are less extensive than in adult patients. Experts in pediatric epilepsy across the region convened at a series of meetings to discuss the use of perampanel in pediatric patients, including dose optimization, AE prevention and management, and considerations in particular groups. This article summarizes key evidence for perampanel in the pediatric population and consolidates the experts' recommendations for using the ASM in managing pediatric epilepsies.

Safety, Awareness, and Familiarity regarding Epilepsy in Teenage Years (SAFETY): understanding the adolescents' perspective about their disease

OBJECTIVE

The objective of this study was to evaluate the understanding of adolescent patients regarding epilepsy.

METHODS

The SAFETY (Safety, Awareness, and Familiarity regarding Epilepsy in Teenage Years) questionnaire (content validity index: 0.96, Flesch readability score: 66.6) was administered to 165 cognitively normal adolescents with epilepsy (85 females, mean age: 15.2 ± 1.6 years, range: 13-18 years). The first part of the questionnaire was devised to evaluate knowledge about epilepsy and antiepileptic medications (SAFETY-K: 7 questions). The second part queried lifestyle modifications and safety (SAFETY-S: 10 questions). Female participants answered 5 additional questions related to reproductive health (RH questionnaire).

RESULTS

The correct response rate for the composite SAFETY questionnaire was 51.5%. The average rates of correct responses for the SAFETY-K and SAFETY-S questions were 47.9% and 53.9%, respectively. On univariate logistic regression analysis, factors which were significant predictors of correct responses included age (odds ratio: 1.8, C.I. = 1.3-2.4), race (Caucasian vs. African-American; odds ratio: 3.9, C.I. = 1.4-10.4), and employment of at least one parent in a professional occupation (odds ratio: 3.3, C.I. = 1.1-10.3). The correct response rate did not correlate with the duration of epilepsy, extent of seizure control, number of antiepileptic medications, parental educational, or (un)employment status. The mean rate of correct responses for the RH questions amongst teenage girls was 17.4%.

CONCLUSIONS

There is lack of awareness about epilepsy and its associated lifestyle modifications in adolescents with epilepsy seen at our institution. This is especially true in young adolescents, African-American patients, and those whose parents are not employed in professional occupations. Teenage girls with epilepsy appear to have limited knowledge with respect to contraception and childbearing.

Advancing the management of childhood epilepsies

Childhood epilepsies comprise a heterogeneous group of disorders and syndromes that vary in terms of severity, prognosis and treatment requirements. Effective management requires early, accurate recognition and diagnosis, and a holistic approach that addresses each individual's medical and psychosocial needs within the context of their overall health status and quality of life. With increasing understanding of underlying aetiologies, new approaches to management and treatment are emerging. For example, genetic testing is beginning to provide a tool to aid differential diagnosis and a means of predicting predisposition to particular types of epilepsy. Despite the availability of an increasing number of antiepileptic drugs (AEDs)--due not only to the development of new AEDs, but also to changes in regulatory requirements that have facilitated clinical development--seizure control and tolerability continue to be suboptimal in many patients, and there is therefore a continuing need for new treatment strategies. Surgery and other non-pharmacological treatments (e.g. vagus nerve stimulation, ketogenic diet) are already relatively well established in paediatric epilepsy. New pharmacological treatments include generational advances on existing AEDs and AEDs with novel modes of action, and non-AED pharmacological interventions, such as immunomodulation. Emerging technologies include novel approaches allowing the delivery of medicinal agents to specific areas of the brain, and 'closed-loop' experimental devices employing algorithms that allow treatment (e.g., electrical stimulation) to be targeted both spatially and temporally. Although in early stages of development, cell-based approaches (e.g., focal targeting of adenosine augmentation) and gene therapy may also provide new treatment choices in the future.

Ideal characteristics of an antiepileptic drug: how do these impact treatment decisions for individual patients?

Effective management of epilepsy requires a holistic approach that takes into account the needs of the individual patient. Antiepileptic drug (AED) treatment must therefore look beyond efficacy to ensure that the patient's overall health status and quality of life (QoL) are optimized. Because the primary objective of AED treatment is to control seizures over the long term, the ideal AED should, first and foremost, demonstrate sustained efficacy and favourable tolerability. In addition, it should have a broad spectrum of activity; its pharmacokinetic profile should be stable and predictable and allow the option of once-daily dosing; and it should not interact with other medications and concomitant AEDs. Because the efficacy of first-line AEDs is broadly comparable, choice of treatment should be based on the individual patient's specific clinical characteristics. In particular, the primary and secondary prevention of comorbid conditions should be taken into consideration, because this can reduce the risk of mortality and improve health outcomes and QoL. Treatment selection must also take into account the patient's particular lifestyle and priorities, to maximize the likelihood of long-term treatment adherence. Advances in genetic testing may help inform choice of treatment - not only by elucidating a patient's underlying aetiology, but also by helping to avoid unnecessary side effects. Although certain patient populations (e.g. women of childbearing potential, adolescents, the elderly) require particular consideration when choosing the most appropriate treatment, every patient's unique clinical characteristics and personal circumstances must be taken into account to ensure treatment success and optimize their QoL.

A profile of adolescent-onset epilepsy

To describe the profile of children with adolescent-onset epilepsy and to determine factors predictive of outcome. A database was searched for all patients with a first seizure between the age of 12 and 16 years. Sixty-five adolescents met inclusion criteria. Ten patients needed at least two medications to control seizures, 36 remained on medication at their last visit and 12 patients had at least 1 seizure in the year preceding. A diagnosis of juvenile myoclonic epilepsy, the presence of coexisting seizures, coexisting myoclonic seizures, age < or =14.5 years at initial diagnosis, and the presence of compliance issues were significantly associated with the need for medication at last visit. Female gender and the presence of compliance issues were associated with the occurrence of at least 1 seizure in the year preceding last visit. A good outcome for adolescent-onset epilepsy can generally be expected in the short term.

Epilepsy in women: special considerations for adolescents

Adolescence is a time of many changes. It is a time of growing independence, physical and emotional change, accompanied by social insecurity. Girls tend to enter puberty ahead of their male peers, growing and changing physically. Our culture tells adolescents that they are still immature, but their bodies are saying otherwise. The adolescents are also becoming aware of themselves as individuals, separate from their parents, and are presented with the challenges of independent thinking and action. If, in the midst of all of these changes, an adolescent is given the diagnosis of a chronic disease such as epilepsy, there is an additional burden. Often the adolescent must go through a variety of emotions, including shame, denial, anger, and sadness. Our role as medical providers is to provide some perspective to the illness and help guide our adolescent patient through the tumultuous emotions of grieving and acceptance. We must provide a foundation of assistance and emotional support, as well as medical knowledge. With a firm but compassionate hand, we can help them cope with their disorder. In this chapter, Drs. Haut and Zupanc explore some of the unique considerations in adolescent women with epilepsy. The first part of the chapter deals with the epidemiologic diagnosis of epilepsy in adolescence, the effect of epilepsy on reproductive health, hormonal influences on epilepsy (including catamenial seizures), and the effects of antiepileptic drugs (AEDs) on hormones, contraception, and bone health. In the second part of the chapter, we deal with the very real psychosocial issues and comorbidities of epilepsy, including quality of life, school performance, depression, migraine headaches, social stigma, and lifestyle changes. In the final section, the authors suggest strategies for clinical patient management.

Bone mineral density with lamotrigine monotherapy for epilepsy

Bone mass, largely accumulated during childhood and adolescence, may be reduced in patients with epilepsy as a result of epilepsy or of antiepileptic medications. Enzyme-inducing medications increase bone-turnover markers, although the effects of newer medications on bone accrual are not well-defined. Total z-score bone mineral density was measured in 13 children, treated with lamotrigine monotherapy, who had never been exposed to other medications, and compared with 36 control subjects and 40 patients exposed to polytherapy. All patients were normally ambulatory and had similar physical activity and calcium intake. The z-scores of bone mineral density for lamotrigine and control subjects were similar (0.52 +/- 0.76 versus 0.49 +/- 0.7) and higher than those receiving polytherapy for 1-5 years (0.14 +/- 0.8, P = 0.12) and >or=6 years (-0.27 +/- 01.15, P < 0.003). Increasing duration of epilepsy was associated with lower bone density for 1-5 years of polytherapy (Spearman's correlation coefficient r = +0.006, P = 0.74) and >or=6 years of polytherapy (Spearman's correlation coefficient r = +0.12, P = 0.13), but not for lamotrigine. These data suggest that lamotrigine may not interfere with bone accrual.

Concerns and Needs of Children With Epilepsy and Their Parents

PURPOSE

Having epilepsy often interferes with a child's and his or her family's quality of life, but specific concerns have not been explored. The purpose of the study was to explore in-depth the self-reported concerns and needs of children with epilepsy and their parents.

METHOD

A focus group methodology was used with 2 child groups and 2 parent groups.

DATA ANALYSIS

Themes were independently identified by each investigator, who then met to discuss the themes until 100% agreement was reached.

RESULTS

Child themes included "talking at my level" and "feeling different from others." Parent themes included "difficulties, struggles and problems," "need for information," and "fears and concerns."

CONCLUSION

Findings from this study suggest that attention needs to be directed to assessing informational and emotional support needs during the diagnostic process. Ongoing assessment is also necessary because children and parents have continuing needs beyond the initial encounter with healthcare professionals.

Epilepsien im Jugendalter

Zusammenfassung: Der Beitrag stellt die Bedeutung chronischer Erkrankungen des Jugendalters im Hinblick auf die Interaktion mit allgemeinen normativen Entwicklungsaufgaben der Adoleszenz dar und spezifiziert dann die besonderen psychosozialen Charakteristika der Epilepsie als häufigste neurologische Erkrankung des Jugendalters. Die besondere Bedeutung der Compliance und Aspekte der Krankheitsbewältigung für Jugendliche mit Epilepsie werden im Hinblick auf wichtige entwicklungspsychologische Themen des Jugendalters diskutiert. Bedeutung und Ziele von Patientenschulung als zentraler Behandlungsbaustein bei chronischen Erkrankungen werden erläutert.